Relmada Therapeutics Inc (NASDAQ:RLMD) Targets NMIBC with Promising Drug Candidate

Core Insights - Relmada Therapeutics Inc is focused on developing therapies for central nervous system disorders, with a significant emphasis on its drug candidate NDV-01 for high-risk non-muscle invasive bladder cancer (NMIBC) [1][6] Stock Performance and Analyst Ratings - Mizuho Securities set a price target of $10 for RLMD, indicating a potential upside of approximately 69.2% from its trading price of $5.91 [2] - The stock has recently experienced a surge of 42% due to positive mid-stage study results for NDV-01, which reported a 12-month complete response rate of 76% [3][6] - Despite the surge, RLMD's current price is $5.91, reflecting a 3.90% decrease from the previous trading session [4] Market Capitalization and Trading Volume - Relmada's market capitalization is approximately $433.4 million, with a trading volume of 1,255,235 shares [4] Future Growth Potential - The promising data from NDV-01 and the planned phase III RESCUE studies, expected to start in mid-2026, could drive future growth for Relmada [5]